Skip to main content
Terug
RMD logo

ResMed Inc.

Datakwaliteit: 100%
RMD
NYSE Healthcare Medical - Instruments & Supplies
€ 228,19
▲ € 0,22 (0,10%)
Marktkapitalisatie: 33,31B
Dagbereik
€ 224,92 € 231,45
52-Weeksbereik
€ 199,92 € 293,81
Volume
1.000.692
50D / 200D Gem.
€ 252,88 / € 260,16
Vorige Slotkoers
€ 227,97

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 23,8 0,4
P/B 5,6 2,9
ROE % 25,9 3,9
Net Margin % 27,2 3,8
Rev Growth 5Y % 12,6 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 295,88 +29.7%
Low: € 265,00 High: € 345,00
Forward K/W
20,6
Forward WPA
€ 11,05
WPA Groei (sch.)
+0,0%
Omzet Sch.
5,6 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 16,20
€ 15,91 – € 16,44
 7,8 B 4
FY2029 € 14,38
€ 14,13 – € 14,59
 7 B 3
FY2028 € 13,43
€ 12,12 – € 14,29
 6,5 B 9

Belangrijkste Punten

Revenue grew 12,64% annually over 5 years — strong growth
Earnings grew 37,20% over the past year
ROE of 25,86% indicates high profitability
Net margin of 27,22% shows strong profitability
Debt/Equity of 0,14 — conservative balance sheet
Generating 1,66B in free cash flow

Groei

Revenue Growth (5Y)
12,64%
Revenue (1Y)9,84%
Earnings (1Y)37,20%
FCF Growth (3Y)72,37%

Kwaliteit

Return on Equity
25,86%
ROIC18,53%
Net Margin27,22%
Op. Margin32,75%

Veiligheid

Debt / Equity
0,14
Current Ratio3,44
Interest Coverage133,66

Waardering

P/E Ratio
23,78
P/B Ratio5,58
EV/EBITDA19,55
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9,84% Revenue Growth (3Y) 10,39%
Earnings Growth (1Y) 37,20% Earnings Growth (3Y) 24,92%
Revenue Growth (5Y) 12,64% Earnings Growth (5Y) 31,08%
Profitability
Revenue (TTM) 5,15B Net Income (TTM) 1,40B
ROE 25,86% ROA 17,14%
Gross Margin 59,36% Operating Margin 32,75%
Net Margin 27,22% Free Cash Flow (TTM) 1,66B
ROIC 18,53% FCF Growth (3Y) 72,37%
Safety
Debt / Equity 0,14 Current Ratio 3,44
Interest Coverage 133,66 Dividend Yield 0,01%
Valuation
P/E Ratio 23,78 P/B Ratio 5,58
P/S Ratio 6,47 PEG Ratio 0,72
EV/EBITDA 19,55 Dividend Yield 0,01%
Market Cap 33,31B Enterprise Value 32,95B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,15B 4,69B 4,22B 3,58B 3,20B
Net Income 1,40B 1,02B 897,56M 779,44M 474,51M
EPS (Diluted) 9,51 6,92 6,09 5,30 3,24
Gross Profit 3,05B 2,66B 2,36B 2,02B 1,84B
Operating Income 1,69B 1,32B 1,13B 1,00B 903,68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,17B 6,87B 6,75B 5,10B 4,73B
Total Liabilities 2,21B 2,01B 2,62B 1,74B 1,84B
Shareholders' Equity 5,97B 4,86B 4,13B 3,36B 2,89B
Total Debt 851,81M 873,94M 1,58B 917,55M 793,72M
Cash & Equivalents 1,21B 238,36M 227,89M 273,71M 295,28M
Current Assets 3,51B 2,36B 2,37B 1,93B 1,57B
Current Liabilities 1,02B 910,66M 758,53M 689,30M 911,77M

Strategiescores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#932 of 1052
24
Custom Capital Light Compounder
#187 of 218
25
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#203 of 332
46
Custom Balanced Risk
#94 of 151
43
Custom Lower Risk
#120 of 140
34

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 25, 2026
Ingestapt Capital Light Compounder
Mar 25, 2026
Ingestapt Balanced Risk
Mar 25, 2026
Ingestapt Lower Risk
Mar 25, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026